Assessment of tuberculosis infection during treatment with biologic agents in a BCG-vaccinated pediatric population

Basit Öğe Kaydı
dc.contributor.authorAtikan, Basak Yildiz
dc.contributor.authorCavusoglu, Cengiz
dc.contributor.authorDortkardesler, Merve
dc.contributor.authorSozeri, Betul
dc.date.accessioned2019-10-27T23:11:31Z
dc.date.available2019-10-27T23:11:31Z
dc.date.issued2016
dc.departmentEge Üniversitesien_US
dc.description.abstractBiologic therapies, such as tumor necrosis factor-alpha (TNF-alpha) blockers, are commonly used to treat rheumatological diseases in childhood. Screening patients for tuberculosis (TB) is highly recommended before starting therapy with TNF-alpha blockers. Despite appropriate screening, TB still remains a problem in patients receiving anti-TNF therapy in countries where TB is not endemic. TB in anti-TNF-treated patients is often diagnosed late due to altered presentation, and this delay results in high morbidity and mortality with a high proportion of extrapulmonary and disseminated disease. The aim of this study is to show the course of TB disease in children who are on biologic therapy, in an era where many of the children are BCG-vaccinated and TB is intermediately endemic. We recruited 71 patients with several types of inflammatory diseases. Six of them had a positive test result during TB screening and began taking isoniazid (INH) prophylactically. During the 3 years of follow-up, none of these patients developed TB disease. Biologic agents can be safely used in a BCG-vaccinated pediatric population, as long as patients are closely monitored to ensure that any cases of TB will be detected early.en_US
dc.identifier.doi10.1007/s10067-014-2842-5en_US
dc.identifier.endpage431en_US
dc.identifier.issn0770-3198
dc.identifier.issn1434-9949
dc.identifier.issue2en_US
dc.identifier.pmid25515621en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage427en_US
dc.identifier.urihttps://doi.org/10.1007/s10067-014-2842-5
dc.identifier.urihttps://hdl.handle.net/11454/53089
dc.identifier.volume35en_US
dc.identifier.wosWOS:000370821300020en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer London Ltden_US
dc.relation.ispartofClinical Rheumatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBCG vaccineen_US
dc.subjectPediatricen_US
dc.subjectTNF blockeren_US
dc.subjectTuberculosisen_US
dc.titleAssessment of tuberculosis infection during treatment with biologic agents in a BCG-vaccinated pediatric populationen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu